文献速递主动脉疾病

非急诊胸降主动脉瘤TEVAR术后3年死亡术前风险评分

Preoperative risk score for mortality within 3 years of nonemergent endovascular repair for descending thoracic aortic aneurysm.
PubMed 文献 · J Vasc Surg · 2025-10-10

基于血管质量倡议(VQI)中3750例非急诊TEVAR治疗的非夹层性胸降主动脉瘤患者,随机分为70%建模队列和30%内部验证队列,建立了3年死亡风险评分。建模与验证队列AUC分别为0.7和0.67,各评分层级死亡率高度一致。

要点

  • 风险评分<3分者TEVAR术后3年死亡率仅2.3%,≥13分者达32.8%。
  • 高龄、COPD用药或吸氧、动脉瘤直径≥6cm、贫血、肾功能不全、术前未用他汀与3年死亡独立相关。
  • 评分在VQI内部验证队列中区分度良好(AUC 0.67),各层级死亡率与建模队列几乎一致。

核心结论

  • 建立了TEVAR治疗非夹层性胸降主动脉瘤后3年死亡的术前风险评分,在VQI内部验证中具有良好准确性和出色一致性。
  • 对生存影响最大的不利因素包括高龄、COPD、动脉瘤直径、贫血、肾功能不全、吸烟、未用他汀和养老院居住状态。

研究设计与样本

  • 回顾性队列研究,数据来源于血管质量倡议(VQI),纳入3750例非急诊TEVAR治疗退行性非夹层性胸降主动脉瘤(锚定区2至5)患者。
  • 患者随机分为70%建模队列用于创建风险评分模型和30%内部验证队列验证评分功能。

主要发现

  • 建模与验证队列在各评分层级死亡率几乎相同、无统计学显著差异;AUC分别为0.7和0.67;Hosmer-Lemeshow拟合总体准确率建模队列88.2%、验证队列87.7%。

关键数值与推荐

  • 建模队列AUC 0.7,验证队列AUC 0.67;Hosmer-Lemeshow总体准确率建模队列88.2%、验证队列87.7%。

临床怎么用

  • 术前可依据年龄、养老院状态、BMI、吸烟、动脉瘤直径、COPD用药/吸氧、肾功能不全、贫血和术前他汀使用计算3年死亡风险评分。
  • 评分<3分提示3年死亡风险低(2.3%),≥13分提示高风险(平均32.8%),可用于术前患者选择和 shared decision-making。

局限性

  • 研究基于VQI数据库,仅进行内部验证,未在外部人群中验证。
  • 仅纳入非急诊、非夹层性胸降主动脉瘤且锚定区2至5的TEVAR患者,结论外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to create a validated risk score for mortality within 3 years of elective endovascular repair (TEVAR) of descending thoracic aortic aneurysm (TAA) based on variables existing at the time of preoperative clinical presentation. METHODS: The Vascular Quality Initiative was queried for nonemergent TEVAR for degenerative, non-dissection-related descending TAAs limited to aortic landing zones 2 to 5. The inclusion criteria were met by 3750 patients. Patients were divided randomly into a 70% testing cohort for risk score model creation and a 30% internal validation cohort to verify the function of the risk score. Binary logistic regression analysis was performed for the outcome of 3-year mortality using variables that achieved a univariable P value of ≤.05. Using this regression, it was determined which variables have a multivariable association for the outcomes as defined by a regression P value of ≤.05. A risk score was then created for the primary outcome. Variables with a multivariable a P value of ≤.05 from the above-mentioned regression were included in the risk score and weighted based on their respective regression beta-coefficient in a point scale. Variables with a beta-coefficient of <0.25 were assigned 0 points, and then a point was added for each rise in beta-coefficient at 0.25 intervals. RESULTS: Significant (P < .05) multivariable association with 3-year mortality was noted for advancing age decade (P < .001), nursing home status (adjusted odds ratio [aOR], 2.63; P = .029), body mass index of <20 kg/m2 (aOR, 1.74; P = .008), active smoking status (aOR, 1.44; P = .023), 6.0 to 6.9 cm TAA diameter (aOR, 1.40; P = .015 relative to <6 cm), ≥7 cm TAA diameter (aOR, 1.97; P < .001 relative to <6 cm), chronic obstructive pulmonary disease (COPD) on medication (aOR, 1.42; P = .029), COPD on oxygen (aOR, 2.29; P < .001), renal insufficiency (aOR, 1.72; P < .001), anemia (aOR, 1.74; P = .001), and lack of statin medication preoperatively (aOR, 1.54; P = .001). There is noted to be significantly upsloping mortality with statistically significant escalation between each risk score bundle. Patients with risk scores of <3 experienced 3-year mortality at just a 2.3% rate, whereas patients with risk scores of ≥13 had a mean 32.8% mortality at 3 years (OR, 21.1; P < .001). There was outstanding agreement between the testing and validation groups at all risk score bundles with nearly identical mortality rates and no statistically significant difference at each level. Area under curve analysis revealed 0.7 and 0.67 for the testing and validation cohorts, respectively. Hosmer-Lemeshow goodness of fit for the source testing regression was 88.2% overall accuracy and for the validation cohort regression was 87.7%. CONCLUSIONS: A risk score for 3-year mortality after TEVAR for non-dissection-related descending TAA has been created which has both good accuracy and outstanding internal Vascular Quality Initiative validation. The most impactful deleterious variables toward survival included advancing age, COPD, aneurysm diameter, anemia, renal insufficiency, tobacco use, lack of statin therapy and nursing home status.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Khan N, Hallare J, Darman L, et al. Preoperative risk score for mortality within 3 years of nonemergent endovascular repair for descending thoracic aortic aneurysm. J Vasc Surg. 2025. PMID: 41077287. doi:10.1016/j.jvs.2025.09.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。